ETI 210

Drug Profile

ETI 210

Alternative Names: ETI-210

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elusys Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Complement activation stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 04 Jul 2005 Data presented at the BIO 2005 Annual International Convention (BIO-2005) have been added to the adverse events and Cancer pharmacodynamics section
  • 09 May 2005 EluSys Therapeutics has completed preclinical studies in Non-Hodgkin's lymphoma
  • 06 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top